Friday, 16 October 2026European Markets

NORWEGIAN AIR SHUT Stock Jumps By 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NORWEGIAN AIR SHUT (Oslo Børs All-share Index_GI: NAS.OL) rose by a staggering 33.72% in 21 sessions from 7.77 kr to 10.39 kr at 01:40 EST on Monday, after three sequential sessions in a row of losses. Oslo Børs All-share Index_GI is jumping 0.37% to 1,418.24 kr, after three sequential sessions in a row of losses.

NORWEGIAN AIR SHUT's last close was 10.52 kr, 23.21% below its 52-week high of 13.70 kr.

About NORWEGIAN AIR SHUT

Norwegian Air Shuttle ASA, together with its subsidiaries, provides scheduled and charter airline services in Norway and internationally. As of December 31, 2021, the company operated a fleet of 70 aircraft. It is also involved in aircraft financing, leasing, and ownership activities; and cargo activities. Norwegian Air Shuttle ASA was founded in 1993 and is headquartered in Fornebu, Norway.

Earnings Per Share

As for profitability, NORWEGIAN AIR SHUT has a trailing twelve months EPS of 0.1 kr.

PE Ratio

NORWEGIAN AIR SHUT has a trailing twelve months price to earnings ratio of 103.9. Meaning, the purchaser of the share is investing 103.9 kr for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.48%.

Yearly Top and Bottom Value

NORWEGIAN AIR SHUT's stock is valued at 10.39 kr at 01:40 EST, way below its 52-week high of 13.70 kr and way higher than its 52-week low of 6.33 kr.

Sales Growth

NORWEGIAN AIR SHUT's sales growth for the current quarter is 168.8%.

Volume

Today's last reported volume for NORWEGIAN AIR SHUT is 6520695 which is 52.3% above its average volume of 3844970.

More news about NORWEGIAN AIR SHUT (NAS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com